Ondansetron treatment in patients with Tourette's syndrome

International Clinical Psychopharmacology

Volumn 14, Issue 6, 1999, Pages 373-376

  Toren, P ^a   Laor, N ^a,b   Cohen, D J ^b   Wolmer, L ^a   Weizman, A ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dopamine; Obsessive compulsive disorder; Ondansetron; Serotonin; Tourette's syndrome

Indexed keywords

HALOPERIDOL; ONDANSETRON; SEROTONIN 3 ANTAGONIST;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; GILLES DE LA TOURETTE SYNDROME; HUMAN; MALE; OBSESSION; PRIORITY JOURNAL; SIDE EFFECT; TIC;

EID: 0032757574     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199911000-00008     Document Type: Article

References (14)

1. Bhadrinath BR (1998) Olanzapine in Tourette syndrome. Br J Psychiatry 172:366.
2. Benline TA, French J (1997) Antiemetic drug effects on cognitive and psychomotor performance: Granisetron vs. ondansetron. Aviat Space Environ Med 68:504-511.
3. Bruun RD, Budman CL (1996) Risperidone as a treatment for Tourette's syndrome. J Clin Psychiatry 57:29-31.
4. Caine ED, Polinsky RJ, Kartzinel R, Ebert MH (1979) The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 136:317-320.
5. Chase, TN, Friedhoff AJ, Cohen DJ (eds) (1992) Tourette Syndrome: Genetics, Neurobiology, and Treatment. New York: Raven Press.
6. Costall B, Domeney AM, Naylor RJ, Tyers MB (1987) Effect of the 5HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 92:881-884.
7. Diemunsch P, Conseiller C, Clyti N, Mamet JP (1997) Ondansetron compared with metoclopramide in the treatment of established postoperative nausea and vomiting. Br J Anaesth 79:322-326.
8. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischman RL, Hill CL, et al. (1989) The Yale-Brown Obsessive Compulsive Scale: I. Development, use, and reliability. Arch Gen Psychiatry 46:1006-1011.
9. Hartman BK, Faris PL, Kim SW, Raymond NC, Goodale RL, Meller WH, Eckert ED (1997) Treatment of bulimia nervosa with ondansetron. Arch Gen Psychiatry 54:969-970.
10. Leckman JF, Towbin KE, Ort SI, Cohen DJ (1988) Clinical assessment of tie disorder severity. In: Tourette Syndrome and Tie Disorders, Clinical Understanding and Treatment (Cohen DJ, Bruun RD, Leckman JF, eds), New York: John Wiley, pp. 55-78.
11. Leckman JF, Riddle MA, Hardin MT (1989) The Yale Global Tie Severity Scale: Initial testing of a clinician-rated scale of tie severity. J Am Acad Child Adolesc Psychiatry 28:566-573.
12. Scahill L, Riddle MA, Hardin MT, Ort SI, King RA, Goodman WK, et al. (1997) Children's Yale-Brown Obsessive Compulsive Scale: Reliability and validity. J Am Acad Child Adolesc Psychiatry 36:844-852.
13. Shapiro AK, Shapiro E (1988) Treatment of tie disorders with haloperidol. In: Tourette's Syndrome and Tie Disorders: Clinical Understanding and Treatment (Cohen DJ, Bruun RD, Leckman JF, eds), New York: Wiley, pp. 267-281.
14. Zoldan J, Friedberg GM, Weizman A, Mclamed E (1996) Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease. Adv Neurol 69:541-544.